Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL4453335 | 0.97 | EGFR (0.68) | EGFR | |
| SCHEMBL4447521 | 0.93 | EGFR (0.79) | EGFR | |
| SCHEMBL4445077 | 0.90 | EGFR (0.67) | EGFRERBB2 | |
| SCHEMBL4453338 | 0.90 | EGFR (0.67) | EGFR | |
| SCHEMBL4447030 | 0.83 | EGFR (0.75) | EGFR | |
| SCHEMBL4452568 | 0.82 | EGFR (1.00) | EGFR | |
| SCHEMBL13600080 | 0.82 | EGFR (0.85) | EGFRERBB2 | |
| SCHEMBL4441308 | 0.82 | EGFR (0.74) | EGFR | |
| SCHEMBL4446647 | 0.82 | EGFR (0.74) | EGFR | |
| SCHEMBL4443490 | 0.82 | EGFR (0.86) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | EGFR 1579/4885ERBB2 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.